Navigation Links
Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008
Date:7/31/2008

n due to the accelerated growth experienced during the first half of 2008 and higher than expected capitalized costs associated with related facilities expansion.

Conference Call Information

A conference call will take place on Thursday, July 31, 2008, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time), hosted by President and CEO Tina Nova Bennett, Ph.D., and other members of senior management. To access the live conference call via phone, dial 800-599-9829 in the U.S. or Canada and 617-847-8703 for international callers. Please specify to the operator that you would like to join the "Genoptix Second Quarter 2008 Earnings Conference Call." The participant code for the call is 23465316. If you are unable to listen to the live webcast, a replay of the call will be available through Thursday, August 7, 2008. Interested parties can access the rebroadcast by dialing 1-888-286-8010 or 1-617-801-6888 internationally and entering the reservation number 31909392.

The conference call will also be webcast live under the investor relations section of the Genoptix website at http://www.genoptix.com. Please connect to the Genoptix website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary. If you are unable to listen to the live webcast, a replay will be available through Friday, August 29, 2008, on the Genoptix website at http://www.genoptix.com.

About Genoptix, Inc.

Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists. Genoptix is headquartered in Carlsbad, California.

Non-GAAP Financial Measures

In addition to disclosing financial results calculated in accordance with generally accepted accounting principles (GAAP), this release contai
'/>"/>

SOURCE Genoptix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Genoptix Reports Strong Financial Results for First Quarter 2008
2. Genoptix Announces Participation at the Bank of America 2008 Healthcare Conference
3. Genoptix Announces 2008 Annual Stockholders Meeting and Date of Record
4. Genoptix Announces Participation at Lehman Brothers 11th Annual Global Health Care Conference
5. Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference
6. Genoptix Announces Pricing of Secondary Public Offering
7. Genoptix Announces Filing of Registration Statement for Secondary Public Offering of Common Stock
8. Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007
9. Genoptix, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 12, 2008
10. Genoptix, Inc. Announces Pricing for Initial Public Offering
11. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2Within3 Expands into Mobile Applications 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 3Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 4Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 1Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 2Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 3Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 4Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 5Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 6URI research couples method targets cancerous tumors 60165 1URI research couples method targets cancerous tumors 60165 2URI research couples method targets cancerous tumors 60165 3URI research couples method targets cancerous tumors 60165 4Scientists are first to observe the global motions of an enzyme copying DNA 10548 1Scientists are first to observe the global motions of an enzyme copying DNA 10548 2Scientists are first to observe the global motions of an enzyme copying DNA 10548 3Scientists are first to observe the global motions of an enzyme copying DNA 10548 4